Category: C.R. Bard
A list of some of the tax tabs for medical device companies for the medical device excise tax during Q1
In January 2013, Medical device companies began paying a 2.3% excise tax on U.S. Sales in order to pay for the Patient Protection and Affordable Care Act.
The levy is expected to generate some $30 billion over the next 10 years.
MassDevice.com is tracking the tally paid by several medical device companies, based on quarterly earnings report for the first quarter of 2013. We will update the list as more companies returns file in.
Tallies based on companies with Q1 earnings ended on March 31, 2013
If you read nothing else today, make sure you're still in the know with MassDevice +3.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
C.R. Bard closes the deal it made last year with federal authorities to settle a probe into its brachytherapy cancer treatment business in return for a $51 million payment.
C.R. Bard (NYSE:BCR) said it closed a deal reached last year with federal prosecutors to settle a probe into its brachytherapy business with a $51 million payment.
Changing expectations affect investors despite unchanged fundamentals: Weaker underlying volumes.
By Stephen Simpson
Profits plunge for medical device company C.R. Bard during the 1st quarter, largely due to a nearly $26 million charge stemming from lawsuits filed over its transvaginal mesh products.
C.R. Bard (NYSE:BCR) saw its 1st-quarter profits plunge on a nearly $26 million charge stemming from the bevy of lawsuits filed against it over its transvaginal mesh products.
But the Murray Hill, N.J.-based medical device company still managed to exceed Wall Street's expectations with its adjusted earnings, leading investors to keep BCR shares about flat today in mid-morning trading.
The U.S. patent office takes a 1st pass at C.R. Bard's stent graft patent and finds it wanting, while an insurance arbitrator denies a $25 million insurance claim stemming from legal claims against its recalled hernia repair products.
C.R. Bard (NYSE:BCR) revealed a 1-2 punch today when it reported another loss in its patent infringement war with W.L. Gore & Assoc. and an adverse insurance decision that could cost it $25 million.
A federal judge stays a patent infringement lawsuit filed by C.R. Bard subsidiary SenoRx over Hologic's Mammosite device for treating breast cancer.
A federal judge in Delaware put a patent infringement spat between C.R. Bard subsidiary SenoRx and Hologic (NSDQ:HOLX) on hold for 90 days last week.